LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lineage Cell Therapeutics Inc (LCTX) does not currently present a strong buy opportunity for a beginner, long-term investor. While the company has promising developments in its pipeline and a recent price target increase from analysts, the lack of significant trading signals, neutral sentiment from hedge funds and insiders, and mixed financial performance suggest that waiting for further developments or a clearer entry point may be more prudent.
The technical indicators show mixed signals. The MACD is above 0 and positively contracting, which is slightly bullish. The RSI is neutral at 39.378, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot point of 1.601, with key support at 1.487 and resistance at 1.716. This suggests limited immediate upside potential.
Analyst B. Riley raised the price target to $4, citing promising developments in the company's corneal endothelial cell therapy (COR
and its differentiated manufacturing approach.
Revenue increased significantly by 130.40% YoY in Q4 2025.
Net income dropped by -126.00% YoY, and EPS fell to 0, signaling profitability concerns.
No recent news or significant trading trends from hedge funds, insiders, or Congress.
Stock trend analysis indicates a 40% chance of a slight decline (-0.94%) in the next day and -1.63% in the next week.
In Q4 2025, revenue increased by 130.40% YoY to $6.6M, and gross margin improved to 99%. However, net income dropped by -126.00% YoY to $851K, and EPS fell to 0, indicating profitability challenges.
B. Riley maintains a Buy rating and raised the price target from $3 to $4, highlighting the company's innovative product pipeline and scalable manufacturing approach.
